All tickers · Prices as of Oct 23, 1:30 PM CT · filings and analysis as of Oct 22, 5:19 PM CT · live price, free
PFE · Pfizer Inc.
Smart-money verdict: ACCUMULATION 2 of 4 cohorts bullish, 0 bearish
Accumulation on PFE — 2 of 4 cohorts bullish, 0 bearish (bullish: insiders, institutions)
Congress trades (90 days)
NEUTRAL
4 disclosed congressional trades on PFE (last 90d): 2 buys, 2 sells
See it live, free →Insiders (SEC Form 4, 90 days)
BULLISH
PFE: 3 insider buy(s) $2,960,110 vs 1 sell(s) $83,261 in last 90d — bullish — insiders buying heavily
See it live, free →Wall St analysts
NEUTRAL
Buy consensus, 32.1% buy ratings, -3.8% target upside
See it live, free →Big funds (13F)
BULLISH
Institutions leaned to accumulation last quarter — 7 of the top 10 holders added, 2 trimmed.
See it live, free →Stock signal (EquityScope)
BUY
$30.02, -1.4% today, -2% to analyst target. Analysis (2026-10-22): PFE trades at 40x trailing earnings but about 10.6x forward, so the valuation depends on depressed 2024-era EPS ($0.76, 6.8% margin) recovering. The stock sits at its 52-week high with low beta (0.28)
See it live, free →
Recent Congress trades in PFE
| Member | Chamber | Type | Amount | Traded |
|---|
| Ro Khanna | House | BUY | $1,001 - $15,000 | 2026-09-11 |
| Carol Devine Miller | House | SELL | $15,001 - $50,000 | 2025-03-10 |
| Ro Khanna | House | BUY | $1,001 - $15,000 | 2026-07-07 |
| Michael Rulli | House | SELL | $1,001 - $15,000 | 2024-11-26 |
| Tommy Tuberville | Senate | SELL | $15,001 - $50,000 | 2026-06-08 |
STOCK Act disclosures arrive 25-45 days after the trade. Insider data from SEC Form 4 (open-market buys and sells only, not grants). Analyst consensus is current.
Data, not investment advice. LoneStarOracle LLC.